tbuckley/cabot-search huggingface dataset:
547P Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)
Authors: T.A. Yap, E.P. Hamilton, T.M. Bauer, E.E. Ileana Dumbrava, R. Jeselsohn, A. Enke, S. Hurley, K.K. Lin, K. Wride, H. Giordano, G. Shapiro
Journal: Annals of Oncology (2020)
912MO A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Authors: L. Zhang, Y. Yang, X. Chen, J. Li, J. Pan, X. He, L. Lin, Y. Shi, W. Feng, J. Xiong, K. Yang, Q. Yu, D. Hu, Y. Sun, Q. Zhang, G. Hu, P. Li, L. Shen, Q. Yang, B. Zhang
Journal: Annals of Oncology (2020)
235P Breast cancer and perceived discrimination in the workplace: A longitudinal cohort study
Authors: G. Ruiz-de-Azua Unzurrunzaga, I.V. Luis, T. Bovagnet, A. Di Meglio, J. Havas, E. Caumette, E. Martin, B. Pistilli, C. Coutant, P.H. Cottu, P. Rouanet, A. Arnaud, O. Arsene, M. Ibrahim, J. Wassermann, R. Rouzier, A-L. Martin, S. Everhard, A. Dumas, G. Menvielle
Journal: Annals of Oncology (2020)
444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
Authors: J.L. Legoux, R. Faroux, N. Barriere, K. Le Malicot, D. Tougeron, V. Lorgis, V. Guérin-Meyer, V. Bourgeois, D. Malka, T. Aparicio, M. Baconnier, V. Lebrun-Ly, J. Egreteau, F. Khemissa Akouz, C. Lepage, V. Boige
Journal: Annals of Oncology (2020)
LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Authors: Z. Lwin, C. Gomez-Roca, E. Saada-Bouzid, E. Yanez, F. Longo Muñoz, S-A. Im, E. Castanon, H. Senellart, D. Graham, M. Voss, M. Doherty, J. Lopez, R. Ghori, P. Kubiak, F. Jin, K. Norwood, H.C. Chung
Journal: Annals of Oncology (2020)

Len (antiangiogenic multiple receptor tyrosine kinase inhibitor) + pembro (anti‒PD-1 agent) showed promising clinical outcomes across several cancers in early-phase trials and is FDA-approved for pts with previously treated advanced endometrial cancer that is not MSI-H or mismatch repair-deficient who are ineligible for curative surgery/radiation. We report the first results from the phase 2 LEAP-005 study (NCT03797326), which evaluates the efficacy and safety of len + pembro in pts with select previously treated advanced solid tumors. This open-label, multicohort study enrolled pts aged ≥18 y with one of the following previously treated, histologically/cytologically confirmed advanced tumors: triple negative breast (TNBC), ovarian, gastric, colorectal (non-MSI-H/mismatch repair proficient), glioblastoma multiforme (GBM), or biliary tract (BTC; ampulla of Vater excluded). Pts received len 20 mg/d + pembro 200 mg Q3W for 35 cycles or until confirmed PD or unacceptable toxicity. Primary endpoints are ORR by blinded independent central review per RECIST v1.1 or RANO (GBM only), and safety. 187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable (Table).Table: LBA41Cohort2L/3L TNBC (n = 31)4L Ovarian (n = 31)3L Gastric (n = 31)3L Colorectal (n = 32)2L GBM (n = 31)2L BTC (n = 31)ORR, % (95% CI)29 (14–48)32 (17–51)10 (2–26)22 (9–40)16 (6–34)10 (2–26)DCR, n (%)18 (58)23 (74)15 (48)15 (47)18 (58)21 (68)DOR, median (range), moNR (0.0+ to 8.4+)NR (1.5+ to 7.9+)NR (2.1+ to 2.3+)NR (2.1+ to 10.4+)3.2 (2.5 to 4.9+)5.3 (2.1+ to 6.2)Grade ≥3 treatment-related AEs, n (%)17 (55)21 (68)13 (42)16 (50)11 (35)15 (48)Discontinued drug due to treatment-related AE, n (%)3 (10)4 (13)2 (6)3 (9)2 (6)2 (6)+, no PD as of last disease assessment; DCR, disease control rate (best confirmed response: complete/partial response; stable disease); DOR, duration of response; NR, not reached. Open table in a new tab +, no PD as of last disease assessment; DCR, disease control rate (best confirmed response: complete/partial response; stable disease); DOR, duration of response; NR, not reached. Len + pembro showed promising antitumor activity and manageable toxicity across the previously treated tumor cohorts evaluated in LEAP-005. The study is ongoing; all cohorts will expand to enroll ≤100 pts/cohort.
Ultrastructural Imaging of Activity-Dependent Synaptic Membrane-Trafficking Events in Cultured Brain Slices
Authors: Cordelia Imig, Francisco José López-Murcia, Lydia Maus, Inés Hojas García-Plaza, Lena Sünke Mortensen, Manuela Schwark, Valentin Schwarze, Julie Angibaud, U. Valentin Nägerl, Holger Taschenberger, Nils Brose, Benjamin H. Cooper
Journal: Neuron (2020)

Electron microscopy can resolve synapse ultrastructure with nanometer precision, but the capture of time-resolved, activity-dependent synaptic membrane-trafficking events has remained challenging, particularly in functionally distinct synapses in a tissue context. We present a method that combines optogenetic stimulation-coupled cryofixation ("flash-and-freeze") and electron microscopy to visualize membrane trafficking events and synapse-state-specific changes in presynaptic vesicle organization with high spatiotemporal resolution in synapses of cultured mouse brain tissue. With our experimental workflow, electrophysiological and "flash-and-freeze" electron microscopy experiments can be performed under identical conditions in artificial cerebrospinal fluid alone, without the addition of external cryoprotectants, which are otherwise needed to allow adequate tissue preservation upon freezing. Using this approach, we reveal depletion of docked vesicles and resolve compensatory membrane recycling events at individual presynaptic active zones at hippocampal mossy fiber synapses upon sustained stimulation.
1295P Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)
Authors: Y. Cheng, Y. He, W. Li, H-L. Zhang, Q. Zhou, B. Wang, C. Liu, A. Walding, M. Saggese, X. Huang, Y. Liu, R. Su, S.S. Ramalingam
Journal: Annals of Oncology (2020)
705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Authors: P. Msaouel, A.O. Siefker-Radtke, R. Sweis, S. Mao, J.E. Rosenberg, U.N. Vaishampayan, A. Rezazadeh Kalebasty, R. Pili, M. Bupathi, L.T. Nordquist, D.R. Shaffer, N. Davis, T. Zhang, S. Gandhi, J. Christensen, R. Shazer, X. Yan, M. Winter, H. Der-Torossian, G. Vasudeva Iyer
Journal: Annals of Oncology (2020)
1958P Reflex screening of somatic BRCA1/2 identifies pathogenic mutations in non-ovarian and breast cancers
Authors: A. Grinshpun, S. Shkedi, A. Zick, N. Hacohen, L. Kaduri, A. Erental, N. Daskal, A. Arad, V. Meiner, E. Pikarsky, T. Peretz
Journal: Annals of Oncology (2020)
Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study
Authors: Manuele Furnari, Leonardo Henry Eusebi, Edoardo Savarino, Carlo Petruzzellis, Gianluca Esposito, Marcello Maida, Luigi Ricciardiello, Silvia Pecere, Andrea Buda, Manuela De Bona, Cristiano Spada, Emilio Di Giulio, Guido Costamagna, Ivo Boskoski, Edoardo G Giannini
Journal: Gut (2020)

COVID-19 pandemic enforced the interruption of routine endoscopic examinations raising the issue of potential delays in the diagnosis of high-risk lesions. We conducted a multicentre study to assess the decrease of GI and pancreato-biliary high-risk lesions detection consequent to the reduction of the endoscopic activity. The lockdown period was compared to the equivalent timeframe of the previous 3 years. Endoscopic procedures decreased by 72.9% (elective 72.4% and urgent 51.3%); the overall cases of high-grade dysplasia/cancers decreased by 59.1% (23.4% pancreato-biliary cancers; 70.6% and 68.8% upper and lower GI lesions). The postemergency period should aim at limiting high-risk lesions delayed diagnoses.

A multicentre, retrospective, cross-sectional study was performed in eight tertiary centres, representative of Northern and Southern Italy, to assess the decrease of GI and pancreato-biliary lesions detected, as a consequence of the reduction of endoscopic procedures caused by the COVID-19 pandemic restrictions. Five were academic centres (62.5%), and all working groups were involved in research activities and training programmes.

We collected data from the pandemic lockdown period from 9 March to 4 May (11°−18° week) of 2020, referred as P2; and the equivalent prepandemic period (11°−18° week) of 2019, referred as P1. Data from the corresponding periods of the previous 2 years (2017 and 2018) were also collected in order to assess trends of the last 3 years.

Main parameters analysed were:

### Endoscopic procedures

The total number of endoscopic procedures performed at the eight centres in P1 was 13 293 (median 1912/centre; IQ 25th–75th: 1135–2691) procedures against 3799 (median 408/centre; IQ 25th–75th: 331–842) performed in P2, thus representing an overall reduction of 71.4% (details shown in figure 1).



Figure 1 
Percentage reduction of the global activities of the endoscopy units in P2 compared with P1. …
1844P Effectiveness of normal saline solution in maintaining the permeability of totally implantable venous catheters in adult cancer patients: Experience of an oncologic center
Authors: F. Macedo, J. Monteiro, R. Félix Soares, A.R. Monteiro, T. Cunha Pereira, S. Baptista, C. Amaral, L. Veloso, C. Gois, N. Bonito, G. Sousa
Journal: Annals of Oncology (2020)
FDA Approval Summary: Entrectinib for the Treatment of <i>NTRK</i> gene Fusion Solid Tumors
Authors: Leigh Marcus, Martha Donoghue, Stephanie Aungst, Claire E. Myers, Whitney S. Helms, Guoxiang Shen, Hong Zhao, Olen Stephens, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2020)

The FDA-approved entrectinib on August 15, 2019, for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Approval was based on demonstration of a durable overall response rate of 57% (95% confidence interval: 43-71), including a complete response rate of 7%, among 54 entrectinib-treated patients with 10 different tumor types harboring an NTRK fusion enrolled in one of three single-arm clinical trials. The durations of response ranged from 2.8 months to 26.0+ months; 68% of responses lasted ≥ 6 months. The most serious toxicities of entrectinib are congestive heart failure, central nervous system effects, skeletal fractures, hepatotoxicity, hyperuricemia, QT prolongation, and vision disorders. Adverse reactions were manageable through dose interruptions (46%), dose reductions (29%), or discontinuation of entrectinib (9%). This is the third approval of a cancer drug for treatment of a tissue agnostic, biomarker-defined cancer.
Covid-19: CDC publishes then withdraws information on aerosol transmission
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

The US Centers for Disease Control and Prevention provoked controversy when it changed information about airborne transmission of covid-19 last week.On Friday 18 September the CDC posted information on its website that for the first time said covid-19 could be spread through "respiratory droplets or small particles, such as those in aerosols, produced when an infected person coughs, sneezes, sings, talks, or breathes.These particles can be inhaled into the nose, mouth, airways, and lungs and cause infection.This is thought to be the main way the virus spreads.
186P Oncologists’ agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2- early breast cancer
Authors: M. Castro-Henriques, D. Casadevall Aguilar, X. Monzonis, M. Martinez-Garcia, T. Martos, A. Corbera, I. Tusquets Trias Bes, J. Albanell, S. Servitja
Journal: Annals of Oncology (2020)
420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients
Authors: T.V. Henriksen, N. Tarazona, T. Reinert, J.A. Carbonell-Asins, D. Roda, M. Huerta, S. Roselló, A.H. Madsen, L.H. Iversen, K.A. Gotschalck, S. Sharma, H-T. Wu, S. Shchegrova, A. Tin, H. Sethi, B. Zimmermann, A. Aleshin, C.L. Andersen, A. Cervantes
Journal: Annals of Oncology (2020)
1029P Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients
Authors: A. Urrizola, B. Solans, R. Sanchez Bayona, L. Mejías, A. Vilalta, S. de la Cruz, B. Olartecoechea, N. Rodríguez-Spiteri, L. Hato, A. Lopez Díaz de Cerio, S. Inoges, M. Santisteban Eslava
Journal: Annals of Oncology (2020)
Worst-Rank Score Methods—A Nonparametric Approach to Informatively Missing Data
Authors: John M. Lachin
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Childhood Violence Exposure With Adolescent Neural Network Density
Authors: Leigh G. Goetschius, Tyler C. Hein, Sara S. McLanahan, Jeanne Brooks-Gunn, Vonnie C. McLoyd, Hailey L. Dotterer, Nestor Lopez-Duran, Colter Mitchell, Luke W. Hyde, Christopher S. Monk, Adriene M. Beltz
Journal: JAMA Network Open (2020)

Adverse childhood experiences are a public health issue with negative sequelae that persist throughout life. Current theories suggest that adverse childhood experiences reflect underlying dimensions (eg, violence exposure and social deprivation) with distinct neural mechanisms; however, research findings have been inconsistent, likely owing to variability in how the environment interacts with the brain.
964P Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways
Authors: C. Romani, L. Lorini, A. Ravaggi, E. Bignotti, A. Paderno, D. Mattavelli, V. Rampinelli, A. Schreiber, M. Ferrari, P. Nicolai, A. Deganello, M. Ravanelli, L. Ardighieri, A. Bozzola, S. Battocchio, P. Castelnuovo, S. Calza, S.M. Magrini, M. Turri Zanoni, P. Bossi
Journal: Annals of Oncology (2020)
CN46 Real-life experience of nurses coordinating device in oral therapy center (DICTO program)
Authors: E. Deluche, T. Darbas, K. Bourcier, L. Montangon, V. Ly Lebrun, J. Pestre, L. Venat, F. Thuillier, E. Nevado, G. Maillan, G. Bayard, E. Caille, S. Chaput, J. Querrioux, C. Suchaud, S. Zabaleta, S. Leobon, N. Tubiana-Mathieu, S. Lavau-Denes
Journal: Annals of Oncology (2020)
1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial
Authors: D. Hochhauser, H. Kindler, P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla, M.J. Hall, J.O. Park, D. Arnold, D-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E.M. O'Reilly, D. McGuinness, K. Cui, K. Schlienger, G. Locker, T. Golan
Journal: Annals of Oncology (2020)
Managing long covid: don’t overlook olfactory dysfunction
Authors: Claire Hopkins, Duika L Burges Watson, Chrissi Kelly, Vincent Deary, Barry C Smith
Journal: BMJ (2020)

“One of the most distressing aspects of living with long covid is the dismissive attitude of some doctors.”1 This quote from Paul Garner in The BMJ resonates closely with views expressed by patients coming to terms with persistent olfactory dysfunction as a consequence of covid-19 infection. Loss of smell and taste is one of the most prevalent symptoms of covid-192 and the best predictor of covid status.23 A substantial proportion of patients experience …
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
Authors: Reinhard Dummer, Paolo A. Ascierto, Paul Nathan, Caroline Robert, Dirk Schadendorf
Journal: JAMA Oncology (2020)

In recent years, the management of metastatic melanoma has been transformed by the emergence of immune checkpoint inhibitors and targeted therapies that significantly improve patient survival. The complementary response kinetics of these treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggest that the optimal combination or sequencing of immune checkpoint inhibitors and targeted therapy may provide additional clinical benefit.Clinical responses to BRAF and/or MEK inhibitors are associated with immune changes within the tumor microenvironment that have the potential to increase the sensitivity of BRAF V600-mutant melanoma to immune checkpoint inhibitors. The combination of immune checkpoint inhibitors with targeted therapy may therefore increase duration of response, improve tumor control, extend survival, and increase the proportion of patients experiencing durable benefit. A targeted therapy-immune checkpoint inhibitor sequencing approach may also be supported by this evidence, but clinical questions regarding optimal timing, duration, and patient selection remain.This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights the results available to date from clinical trials exploring these approaches to treatment. Several late-stage trials are under way looking to answer open questions in this field and address the continuing debate surrounding up-front combination vs sequencing. As phase 3 data have begun to emerge, trial designs and available data from key studies are discussed in the context of their resultant implications for clinical practice.
LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
Authors: L. Zuur, J.L. Vos, J.B. Elbers, O. Krijgsman, X. Qiao, A. van der Leun, L. Smit, M.W. van den Brekel, B. Tan, B. Jasperse, W.V. Vogel, S.M. Willems, A. Al-Mamgani, D. Peeper, T.N. Schumacher, C.U. Blank, J.P. de Boer, J.B.A.G. Haanen
Journal: Annals of Oncology (2020)
1650P Desmoid type fibromatosis in patients
Authors: S. Bouttefroy, N. Penel, V. Minard-Colin, D. Orbach, A. Le Cesne, J-Y. Blay, P. Marec Berard, C. Verité, V. Laurence, S. Piperno-Neumann, A-S. Defachelles, E. Bompas, C.M. Chevreau, F. Duffaud, S. Salas, M. Morelle, M. Jean Denis, A. Italiano, S. Bonvalot, N. Corradini
Journal: Annals of Oncology (2020)
1451P Comparative response evaluation of cisplatin-capecitabine with cisplatin-5-fluorouracil in advanced gastric carcinoma: A quasi-experimental study
Authors: A. Hoque, S. Alam, M.A. Bari, M.S.U. Matin, R.K. Bhowmick, A. Chowdhury, I.U. Rahim, A.K. Thakur, T. Ahmed
Journal: Annals of Oncology (2020)
838P TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
Authors: A. Michael, W. Wilson, R. Harrop, I. McNeish, R. Lord, D. Blount, A.R. Clamp, M. Feeney, L. Farrelly, L. Hanna, R. Kristeleit, S. Nicum, A. Walther, O. Pressey, A. Hackshaw, J.A. Ledermann
Journal: Annals of Oncology (2020)
CXCR4 induces cell autophagy and maintains EBV latent infection in EBVaGC
Authors: Weiwen Wang, Yan Zhang, Wen Liu, Xiangyan Zhang, Hua Xiao, Menghe Zhao, Bing Luo
Journal: Theranostics (2020)

Rationale: Epstein-Barr virus (EBV) is found in ~7% of gastric carcinoma cases worldwide, and all tumour cells harbour the clonal EBV genome. EBV can regulate pathways and protein expression to induce gastric carcinoma; however, the molecular mechanism underlying EBV-associated gastric carcinoma (EBVaGC) remains elusive. Methods: GEO microarray and molecular experiments were performed to compare CXCR4 expression between EBV-positive and EBV-negative gastric carcinoma (EBVnGC). Transfections with LMP2A plasmid or siRNA were carried out to assess the role of LMP2A in CXCR4 expression. The effects and mechanisms of CXCR4 on cell autophagy were analysed in vitro using molecular biological and cellular approaches. Additionally, we also determined the regulatory role of CXCR4 in latent EBV infection. Results: CXCR4 expression was significantly upregulated in EBVaGC tissues and cell lines. LMP2A could induce AKT phosphorylation to increase NRF1 expression, thereby binding to the CXCR4 promoter to increase its transcriptional level. Moreover, CXCR4 promoted ZEB1 expression to upregulate ATG7 synthesis, which could then activate autophagy. Moreover, CXCR4 increased the number of cells entering the G2/M phase and inhibited cell apoptosis via the autophagy pathway. Finally, CXCR4 knockdown was associated with elevated BZLF1 expression, but this effect was not influenced by autophagy. Conclusions: Our data suggested new roles for CXCR4 in autophagy and EBV replication in EBVaGC, which further promoted cell survival and persistent latent infection. These new findings can lead to further CXCR4-based anticancer therapy.
398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
Authors: C. Lepage, J.M. Phelip, L. Cany, E. Barbier, S. Manfredi, P. Deguiral, R. Faroux, M. Baconnier, D. Pezet, J. Duchmann, E. Terrebonne, A. Adenis, M. Benabdelghani, J. Ain, G. Breysacher, I. Boillot-Benedetto, A. Pelaquier, P. Prost, A. Lievre, O. Bouche
Journal: Annals of Oncology (2020)
1977O Functional inactivation of E-cadherin drives EMT-less metastasis
Authors: S. Alberti, E. Guerra, R. Lattanzio, M. Ceci, K. Boujnah, S. Briguori, V. Garbo, A. Moschella, D.F. Altomare, R. Depalo, M.T. Rotelli, A. Picciariello, M. Trerotola
Journal: Annals of Oncology (2020)
1647P Evaluation of baseline neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR) and lymphocyte to monocyte ratios (LMR) as prognostic factors in osteosarcoma – The Toronto Sarcoma Program Experience
Authors: O. Ayodele, A. Griffin, P. Ferguson, A. Gupta, J. Wunder, A. Abdul Razak
Journal: Annals of Oncology (2020)
731P The impact of proton pump inhibitors on pazopanib exposure
Authors: S.D. Krens, F. Lubberman, M. Van Egmond, F. Jansman, D. Burger, P. Hamberg, W. Vervenne, H. Gelderblom, I.M.E. Desar, C. Van Herpen, N. Van Erp
Journal: Annals of Oncology (2020)
1180P Single-institution real-life experience of 177Lu-DOTATATE treatment in progressive, well differentiated GEPNETs
Authors: F. Scalorbi, F. Scalorbi, A. Lorenzoni, V. Fuoco, G. Argiroffi, N. Prinzi, S. Pusceddu, G. Aliberti, J. Coppa, F.G.M. De Braud, V. Mazzaferro, E. Seregni
Journal: Annals of Oncology (2020)